AWM
SUPN icon

Abound Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Abound Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$207 – 1555
2026
Q1 		$207 Hold
4
– – ﹤0.01% 1229
2025
Q4 		$199 Hold
4
– – ﹤0.01% 1182
2025
Q3 		$192 Hold
4
– – ﹤0.01% 1132
2025
Q2 		$127 Hold
4
– – ﹤0.01% 1193
2025
Q1 		$131 Sell
4
-2
-33% -$71 ﹤0.01% 1164
2024
Q4 		$217 Hold
6
– – ﹤0.01% 1024
2024
Q3 		$188 Sell
6
-6
-50% -$187 ﹤0.01% 1203
2024
Q2 		$321 Hold
12
– – ﹤0.01% 965
2024
Q1 		$410 Hold
12
– – ﹤0.01% 977
2023
Q4 		$348 Buy
+12
New +$318 ﹤0.01% 1092

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Abound Wealth Management's SUPN Position: Q2 2026 in Review

Abound Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 4 shares — an estimated $207 sold.

Abound Wealth Management first reported a position in SUPN in Q4 2023 and held it in 10 quarters. The position peaked at $410 in Q1 2024. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Abound Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Abound Wealth Management sold 4 Supernus Pharmaceuticals shares in Q2 2026, an estimated $207.
  • Abound Wealth Management first reported a position in Supernus Pharmaceuticals in Q4 2023 and held it in 10 quarters.
  • Abound Wealth Management's Supernus Pharmaceuticals position peaked at $410 in Q1 2024.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.